Catalyst Funds Management’s DexCom DXCM Stock Holding History

Catalyst Funds Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,940	Closed	-$247K	–	724
2026 Q1	$247K	Buy	+3,940	New	+$274K	0.04%	409
2025 Q1	–	Sell	-10,200	Closed	-$793K	–	501
2024 Q4	$793K	Buy	+10,200	New	+$755K	0.19%	107
2024 Q2	–	Sell	-300	Closed	-$41.6K	–	1278
2024 Q1	$41.6K	Buy	+300	New	+$37.7K	0.01%	608

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Catalyst Funds Management's DXCM Position: Q2 2026 in Review

Catalyst Funds Management sold out of DexCom (DXCM) in Q2 2026, closing a stake of 3,940 shares — an estimated $247K sold.

Catalyst Funds Management first reported a position in DXCM in Q1 2024 and held it in 3 quarters. The position peaked at $793K in Q4 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Catalyst Funds Management reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
Catalyst Funds Management sold 3,940 DexCom shares in Q2 2026, an estimated $247K.
Catalyst Funds Management first reported a position in DexCom in Q1 2024 and held it in 3 quarters.
Catalyst Funds Management's DexCom position peaked at $793K in Q4 2024.
968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.